Nucleotide substitution patterns can predict the requirements for drug-resistance of HIV-1 proteins.
about
The biased nucleotide composition of the HIV genome: a constant factor in a highly variable virusGenetic variation and susceptibilities to protease inhibitors among subtype B and F isolates in BrazilSequence and drug susceptibility of subtype C reverse transcriptase from human immunodeficiency virus type 1 seroconverters in ZimbabweDifferential binding of tenofovir and adefovir to reverse transcriptase of hepatitis B virusHIV-1 drug resistance and resistance testing.Adaptation of HIV-1 depends on the host-cell environment.Increased multinucleoside drug resistance and decreased replicative capacity of a human immunodeficiency virus type 1 variant with an 8-amino-Acid insert in the reverse transcriptase.Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconvertors infected with zidovudine-resistant variants.Forced evolution of a regulatory RNA helix in the HIV-1 genomeClinical data sets of human immunodeficiency virus type 1 reverse transcriptase-resistant mutants explained by a mathematical model.Drug resistance and antiretroviral drug development.Human immunodeficiency virus type 1 escape is restricted when conserved genome sequences are targeted by RNA interferenceSelection of T1249-resistant human immunodeficiency virus type 1 variants.HIV-1 reverse transcriptase nucleotide substitutions in subtype C-infected, drug-naive, and treatment-experienced patients in South India.Detailed mechanistic insights into HIV-1 sensitivity to three generations of fusion inhibitors.Estimation of the HIV-1 backward mutation rate from transmitted drug-resistant strains.Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor.The impact of unprotected T cells in RNAi-based gene therapy for HIV-AIDS.HIV-1 evolution: frustrating therapies, but disclosing molecular mechanisms.Comparative study of the genetic barriers and pathways towards resistance of selective inhibitors of hepatitis C virus replication.The impact of HIV-1 genetic diversity on the efficacy of a combinatorial RNAi-based gene therapy.Modification of the Tet-On regulatory system prevents the conditional-live HIV-1 variant from losing doxycycline-control.Combination of the R263K and M184I/V resistance substitutions against dolutegravir and lamivudine decreases HIV replicative capacity.Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus.Exploitation of the low fidelity of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase and the nucleotide composition bias in the HIV-1 genome to alter the drug resistance development of HIV.Initial appearance of the 184Ile variant in lamivudine-treated patients is caused by the mutational bias of human immunodeficiency virus type 1 reverse transcriptaseBroad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codons 41 and 215.HIV-1 tolerates changes in A-count in a small segment of the pol gene.Second site escape of a T20-dependent HIV-1 variant by a single amino acid change in the CD4 binding region of the envelope glycoprotein.HIV drug resistance in HIV positive individuals under antiretroviral treatment in Shandong Province, China.Impact of the HIV integrase genetic context on the phenotypic expression and in vivo emergence of raltegravir resistance mutations.Substitutions in the Reverse Transcriptase and Protease Genes of HIV-1 Subtype B in Untreated Individuals and Patients Treated With Antiretroviral DrugsMutation patterns for two flaviviruses: hepatitis C virus and GB virus C/hepatitis G virus.Sanger and Next Generation Sequencing Approaches to Evaluate HIV-1 Virus in Blood Compartments
P2860
Q24498670-348A1C3A-CDF6-4CE2-8302-945E580BF33FQ28369565-FB3113BA-C3AD-4DEC-AABD-960CAE96B519Q28378993-F4628792-777E-4CAF-950F-97657D702D7BQ28542705-86BED86C-9D33-4256-95C2-7A1FD7A1E52CQ30245693-BCFC7532-222F-430D-B7DD-C73700C9F3D7Q33277177-5F5D2D58-AE2C-4EF9-924F-92223DEB10FBQ33737755-2D30707B-DA71-4CB6-B928-B82AD7A60672Q33782562-3C684103-F0C4-468E-9DCA-6847D3FB755EQ34626639-3354CB7F-DAE8-4310-B7B4-3AF4EE428AE1Q35874788-C9D52F6F-11FA-461D-A80D-729C311654F9Q36104277-033D8CEE-C85A-4AE4-B5AB-444BD8204657Q36483991-89F27ECD-788A-4AD9-B256-353382E6ED07Q36748009-A00F4955-B087-4850-B96B-2F1BAAA802A0Q37388226-6A331564-5D7B-4C49-B4AB-89B691186ED1Q37446872-937480A2-0F05-4FC4-A328-9C8E2745F765Q37447287-0F8FF4E2-C487-4E03-A21F-4FA1AF4899CEQ37596642-7DE5BC47-3B7E-4559-899D-90C4AF89F404Q37620810-DA699CB2-2BD7-443B-B7D2-4357FCE601C4Q37755873-A0B7D3EF-3A6A-4971-9768-9A56EF013C0CQ38283239-25274E58-4CFF-4EBB-887C-1E9AE8423AD2Q39035301-2495246A-5EB0-4C96-B6F1-75AB6272A2A8Q39136662-D5A8F594-EC92-4BB4-85D6-7FCE3619A89EQ39564517-EF0944EC-64B9-4FB2-9414-5FE660DE4B98Q39601389-8F7CC70E-25CD-49CC-8CE7-CF1657095601Q39603104-B3360623-1EB2-4335-BE49-815403B3E6D2Q39879230-5F125885-308F-4639-9B18-0713CC7AC9DAQ39879896-2663D362-F426-4EC1-90B9-30579C7ECFA8Q40058710-2B981EDB-2BF8-4002-AFB6-FB25BE7F7D04Q40203143-16876FE5-220F-4E87-8267-2AE8C5D4422EQ41153137-BD6D8351-39C3-43C1-A1C4-FFD4BC998707Q42183134-CF21F3DA-228F-4F74-BF30-444432C851ADQ42551705-AF435570-FB87-400A-815C-4E0B354580ADQ42993810-2835FE8A-0A64-4DA6-B87B-B56A7BE3AE0BQ58792426-0B5B6206-39AA-44ED-A2E0-7A545EF89B70
P2860
Nucleotide substitution patterns can predict the requirements for drug-resistance of HIV-1 proteins.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh-hant
name
Nucleotide substitution patter ...... -resistance of HIV-1 proteins.
@en
Nucleotide substitution patter ...... -resistance of HIV-1 proteins.
@nl
type
label
Nucleotide substitution patter ...... -resistance of HIV-1 proteins.
@en
Nucleotide substitution patter ...... -resistance of HIV-1 proteins.
@nl
prefLabel
Nucleotide substitution patter ...... -resistance of HIV-1 proteins.
@en
Nucleotide substitution patter ...... -resistance of HIV-1 proteins.
@nl
P2093
P1433
P1476
Nucleotide substitution patter ...... -resistance of HIV-1 proteins.
@en
P2093
P356
10.1016/0166-3542(96)00944-8
P577
1996-06-01T00:00:00Z